James moved back to the UK in 1997 to the recently formed Leukocyte Biology Section within the NHLI at Imperial College London. There his interests included the identification of binding sites of prototypic small molecule antagonists of chemokine receptors with obvious therapeutic potential in a wide range of diseases. Current research interests of the group include other aspects of chemokine biology including regulation and trafficking of receptors, their role in disease and also the efforts of microbes to circumvent the chemokine system. Funding for the research comes from Arthritis UK, BBSRC, British Heart Foundation, MRC, Wellcome Trust and collaborations with pharmaceutical companies both in the UK and abroad.